影像学对比剂与肾脏
碘对比剂血管内暴露可致对比剂相关急性肾损伤,通常表现为给药后数日内轻度一过性肾功能下降,与不良结局相关但因果未证实;钆对比剂在严重肾功能不全者中可致肾源性系统性纤维化。重症患者常需使用对比剂,临床医生应掌握其风险因素、发生率及预防证据,以进行循证风险获益评估。
要点
- 对比剂相关急性肾损伤通常为给药后数日内轻度一过性肾功能下降,与不良结局相关但因果未证实。
- 碘对比剂血管内暴露是急性肾损伤的潜在并发症,严重肾功能不全者使用钆对比剂可能发生肾源性系统性纤维化。
- 有证据提示慢性肾脏病患者中临床必需的潜在救命影像检查使用不足,可能与医生担心诱发对比剂相关急性肾损伤有关。
核心结论
- 对比剂相关急性肾损伤特征性的血清肌酐轻度升高与严重不良结局之间的因果关系尚未证实。
- 严重肾功能不全患者使用钆对比剂与肾源性系统性纤维化相关。
- 重症监护医生等应掌握对比剂相关结局的风险因素、发生率及预防的实证数据,以进行循证风险获益评估。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 对比剂相关急性肾损伤通常表现为对比剂给药后数日内出现的轻度、一过性肾功能下降。
- 对比剂相关急性肾损伤与包括进行性肾功能障碍和死亡在内的严重不良结局相关。
- 有证据提示慢性肾脏病患者中临床必需的潜在救命影像学操作使用不足,假设与医生担心诱发对比剂相关急性肾损伤有关。
- 钆对比剂血管内给药与严重肾功能不全患者发生肾源性系统性纤维化相关。
关键数值与推荐
- 原文未报告关键数值或推荐条款。
临床怎么用
- 原文未据此给出推荐。
局限性
- 对比剂相关急性肾损伤特征性的血清肌酐轻度升高与严重不良结局之间的因果关系尚未证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AKI is a potential complication of intravascular iodinated contrast exposure. Contrast-associated AKI, which typically manifests as small and transient decrements in kidney function that develop within several days of contrast administration, is associated with serious adverse outcomes, including progressive kidney dysfunction and death. However, a causal link between the small increases in serum creatinine that characteristically occur with contrast-associated AKI and serious adverse outcomes remains unproven. This is important given mounting evidence that clinically indicated, potentially lifesaving radiographic procedures are underutilized in patients with CKD. This has been hypothesized to be related to provider concern about precipitating contrast-associated AKI. Intravascular gadolinium-based contrast, an alternative to iodinated contrast that is administered with magnetic resonance imaging, has also been linked with potential serious adverse events, notably the development of nephrogenic systemic fibrosis in patients with severe impairment in kidney function. Patients hospitalized in the intensive care unit frequently have clinical indications for diagnostic and therapeutic procedures that involve the intravascular administration of contrast media. Accordingly, critical care providers and others treating critically ill patients should possess a sound understanding of the risk factors for and incidence of such outcomes, the ability to perform evidence-based risk-benefit assessments regarding intravascular contrast administration, and knowledge of empirical data on the prevention of these iatrogenic complications.
引用
- Cashion W, Weisbord SD. Radiographic Contrast Media and the Kidney. Clin J Am Soc Nephrol. 2022. PMID: 35777831. doi:10.2215/CJN.16311221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。